SCNI
Scinai Immunotherapeutics Ltd
$
1.270
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.5499
Open
1.370
VWAP
1.32
Vol
143.66K
Mkt Cap
4.05M
Low
1.1801
Amount
189.29K
EV/EBITDA(TTM)
--
Total Shares
581.14K
EV
9.39M
EV/OCF(TTM)
--
P/S(TTM)
1.44
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Show More
Valuation Metrics
The current forward P/E ratio for Scinai Immunotherapeutics Ltd (SCNI.O) is 0.00, compared to its 5-year average forward P/E of -22.45. For a more detailed relative valuation and DCF analysis to assess Scinai Immunotherapeutics Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-22.45
Current PE
0.00
Overvalued PE
70.98
Undervalued PE
-115.89
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
1.40
Overvalued PS
0.09
Undervalued PS
-0.08
Financials
Annual
Quarterly
FY2024Q4
206.00K
Total Revenue
FY2024Q4
YoY :
+25.62%
-2.29M
Operating Profit
FY2024Q4
YoY :
-4.29%
-2.23M
Net Income after Tax
FY2024Q4
YoY :
-100.00%
0.00
EPS - Diluted
FY2024Q4
YoY :
-26.25%
-1.08M
Free Cash Flow
FY2025Q2
YoY :
+184.48%
-164.29
Gross Profit Margin - %
FY2025Q2
-497.38
FCF Margin - %
FY2025Q2
YoY :
-34.59%
-534.80
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SCNI News & Events
Events Timeline
2025-07-29 (ET)
2025-07-29
07:26:53
Scinai Immunotherapeutics' PC111 featured in peer-reviewed publication
2025-03-05 (ET)
2025-03-05
07:31:58
Scinai Immunotherapeutics announces $10M standby equity purchase agreement
2025-03-04 (ET)
2025-03-04
17:28:27
Scinai Immunotherapeutics files to sell 3.02M ADS for holders
Sign Up For More Events
Sign Up For More Events
News
9.0
07-29NewsfilterScinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN
9.5
07-29BenzingaWhy Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
7.5
06-26PRnewswireScinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"
Sign Up For More News
People Also Watch
XXII
22nd Century Group Inc
1.550
USD
+2.65%
GNLN
Greenlane Holdings Inc
3.150
USD
-2.17%
SGD
Safe and Green Development Corp
1.020
USD
-2.86%
SNES
Senestech Inc
3.290
USD
-0.90%
SISI
Shineco Inc
0
USD
0.00%
TRNR
Interactive Strength Inc
2.590
USD
+4.86%
TCRT
Alaunos Therapeutics Inc
2.710
USD
-0.37%
MTNB
Matinas BioPharma Holdings Inc
1.340
USD
-2.90%
FAQ
What is Scinai Immunotherapeutics Ltd (SCNI) stock price today?
The current price of SCNI is 1.27 USD — it has decreased -9.29 % in the last trading day.
What is Scinai Immunotherapeutics Ltd (SCNI)'s business?
What is the price predicton of SCNI Stock?
What is Scinai Immunotherapeutics Ltd (SCNI)'s revenue for the last quarter?
What is Scinai Immunotherapeutics Ltd (SCNI)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Scinai Immunotherapeutics Ltd (SCNI)'s fundamentals?
How many employees does Scinai Immunotherapeutics Ltd (SCNI). have?